Abstracts tagged "diagnosis and lymphocytes"

Abstract Number: 41 • 2017 ACR/ARHP Annual Meeting
A Fine Bioinformatical Analysis of Lymphocyte Distribution Predicts the Diagnosis of Systemic Autoimmune Diseases
Quentin Simon¹, Bénédicte Rouvière¹, Tifenn Martin¹, Lucas Le Lann¹, Alain Saraux¹, Valérie Devauchelle-Pensec¹, Concepcion Marañón², Nieves Varela Hernández², Aleksandra Dufour³, Carlo Chizzolini⁴, Ellen de Langhe⁵, Nuria Barbarroja⁶, Chary Lopez-Pedrera⁷, Velia Gerl⁸, Aurelie Degroof⁹, Julie Ducreux¹⁰, Elena Trombetta¹¹, Tianlu Li¹², Marta Alarcón-Riquelme¹³, Christophe Jamin¹ and Jacques-Olivier Pers¹, ¹U1227, Université de Brest, Inserm, Labex IGO, CHU de Brest, Brest, France, ²GENYO, Centre for Genomics and Oncological Research Pfizer, University of Granada, Andalusian Regional Government, Granada, Spain, ³Immunology & Allergy, University Hospital and School of Medicine, Geneva, Switzerland, ⁴University hospital of Geneva, Geneva, Switzerland, ⁵Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ⁶Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/ University of Cordoba, Cordoba, Spain, ⁸Department of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁹Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹⁰Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Laboratorio di Analisi Chimico Cliniche e Microbiologia - Servizio di Citofluorimetria, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ¹²Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, ¹³GENYO. Center for Genomics and Oncological Research, Granada, Spain
Background/Purpose : We investigated 194 individuals with SADs (38 primary Sjögren’s syndrome (pSS), 47 rheumatoid arthritis (RA), 46 systemic lupus erythematosus (SLE), 42 systemic sclerosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].